JP2015509983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509983A5 JP2015509983A5 JP2015500493A JP2015500493A JP2015509983A5 JP 2015509983 A5 JP2015509983 A5 JP 2015509983A5 JP 2015500493 A JP2015500493 A JP 2015500493A JP 2015500493 A JP2015500493 A JP 2015500493A JP 2015509983 A5 JP2015509983 A5 JP 2015509983A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutically acceptable
- solvate
- ester
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 54
- 150000002148 esters Chemical class 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 239000012453 solvate Substances 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 239000003814 drug Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 0 *[C@@]([C@@]1*)[C@@](CO*)O[C@@]1(*)c1cnc2[n]1N=C(*)NC2* Chemical compound *[C@@]([C@@]1*)[C@@](CO*)O[C@@]1(*)c1cnc2[n]1N=C(*)NC2* 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 2
- 229950008454 favipiravir Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940126181 ion channel inhibitor Drugs 0.000 description 2
- 229950004244 laninamivir Drugs 0.000 description 2
- UKTIJASCFRNWCB-RMIBSVFLSA-N laninamivir octanoate hydrate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O UKTIJASCFRNWCB-RMIBSVFLSA-N 0.000 description 2
- 229950005327 laninamivir octanoate hydrate Drugs 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- 108700013356 oplunofusp Proteins 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 2
- 229960001084 peramivir Drugs 0.000 description 2
- 239000000651 prodrug Chemical group 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UGGITRSRFHZMKU-WEIZIPMPSA-N radavirsen Chemical compound N1([C@H]2CN(C[C@H](O2)COP(=O)(N(C)C)N2CCN(CC2)C(=O)OCCOCCOCCO)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CN(C2)P(=O)(OC[C@H]2O[C@H](CNC2)N2C(NC(=O)C(C)=C2)=O)N(C)C)N2C(NC(=O)C(C)=C2)=O)N(C)C)N2C(NC(=O)C(C)=C2)=O)N2CCNCC2)N2C(N=C(N)C=C2)=O)N(C)C)N2C(NC(=O)C(C)=C2)=O)N(C)C)N2C3=NC=NC(N)=C3N=C2)N(C)C)N2C(N=C(N)C=C2)=O)N(C)C)N2C(NC(=O)C(C)=C2)=O)N2CCNCC2)N2C(N=C(N)C=C2)=O)N(C)C)N2C3=NC=NC(N)=C3N=C2)N(C)C)N2C3=C(C(NC(N)=N3)=O)N=C2)N(C)C)N2C3=NC=NC(N)=C3N=C2)N(C)C)N2C3=NC=NC(N)=C3N=C2)N(C)C)N2C3=C(C(NC(N)=N3)=O)N=C2)N(C)C)N2C3=NC=NC(N)=C3N=C2)N(C)C)N2C(NC(=O)C(C)=C2)=O)N2CCNCC2)N2C(NC(=O)C(C)=C2)=O)N(C)C)N2C3=C(C(NC(N)=N3)=O)N=C2)N(C)C)N2C3=C(C(NC(N)=N3)=O)N=C2)N(C)C)C=CC(N)=NC1=O UGGITRSRFHZMKU-WEIZIPMPSA-N 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- VYTMBMLLTQRIFQ-GBNDHIKLSA-N N/C(/c1ncc([C@@H]([C@@H]2F)O[C@H](CO)[C@H]2O)[nH]1)=N/C(N)=N Chemical compound N/C(/c1ncc([C@@H]([C@@H]2F)O[C@H](CO)[C@H]2O)[nH]1)=N/C(N)=N VYTMBMLLTQRIFQ-GBNDHIKLSA-N 0.000 description 1
- OVEMXIFZUWQYFQ-GBNDHIKLSA-O NC(NC(c1ncc([C@@H]([C@@H]2F)O[C@H](CO)[C@H]2O)[nH]1)=O)=[NH2+] Chemical compound NC(NC(c1ncc([C@@H]([C@@H]2F)O[C@H](CO)[C@H]2O)[nH]1)=O)=[NH2+] OVEMXIFZUWQYFQ-GBNDHIKLSA-O 0.000 description 1
- KZBZJHYUYNFNGZ-JWMKEVCDSA-N NC1=NC(N)=NN2C1=NCC2[C@@H]([C@@H]1F)O[C@H](CO)[C@H]1O Chemical compound NC1=NC(N)=NN2C1=NCC2[C@@H]([C@@H]1F)O[C@H](CO)[C@H]1O KZBZJHYUYNFNGZ-JWMKEVCDSA-N 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610411P | 2012-03-13 | 2012-03-13 | |
| US61/610,411 | 2012-03-13 | ||
| PCT/US2013/030196 WO2013138236A1 (en) | 2012-03-13 | 2013-03-11 | 2'- substituted carba-nucleoside analogs for antiviral treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017121389A Division JP6525441B2 (ja) | 2012-03-13 | 2017-06-21 | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509983A JP2015509983A (ja) | 2015-04-02 |
| JP2015509983A5 true JP2015509983A5 (cg-RX-API-DMAC7.html) | 2016-04-07 |
| JP6242378B2 JP6242378B2 (ja) | 2017-12-06 |
Family
ID=47997868
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500493A Active JP6242378B2 (ja) | 2012-03-13 | 2013-03-11 | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
| JP2017121389A Active JP6525441B2 (ja) | 2012-03-13 | 2017-06-21 | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
| JP2018242679A Withdrawn JP2019069986A (ja) | 2012-03-13 | 2018-12-26 | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017121389A Active JP6525441B2 (ja) | 2012-03-13 | 2017-06-21 | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
| JP2018242679A Withdrawn JP2019069986A (ja) | 2012-03-13 | 2018-12-26 | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9481704B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3351552B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6242378B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102068856B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104185638A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013232378B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2866381C (cg-RX-API-DMAC7.html) |
| EA (2) | EA201791916A1 (cg-RX-API-DMAC7.html) |
| ES (4) | ES2709071T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL234586A (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN08505A (cg-RX-API-DMAC7.html) |
| MD (1) | MD4496C1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX355267B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ629996A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2834258T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2834258T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2834258T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013138236A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009323766B2 (en) | 2008-12-02 | 2016-10-06 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US8633198B1 (en) | 2011-09-20 | 2014-01-21 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| SI2834258T1 (sl) | 2012-03-13 | 2017-04-26 | Gilead Sciences, Inc. | 2'-substituirani karba-nukleozidni analogi za protivirusno zdravljenje |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UA113980C2 (uk) * | 2012-03-21 | 2017-04-10 | Аліос Біофарма, Інк. | Заміщені нуклеозиди, нуклеотиди і їх аналоги |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| AU2013407264B2 (en) * | 2013-12-11 | 2016-09-29 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza a RNA-dependent RNA polymerase |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| EP3102215B1 (en) * | 2014-02-06 | 2021-06-16 | Riboscience LLC | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| EA031726B1 (ru) | 2014-09-26 | 2019-02-28 | Рибосайенс Ллк | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса |
| CN107427529A (zh) | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
| RU2720811C2 (ru) | 2015-09-23 | 2020-05-13 | Мерк Шарп И Доум Лимитед | 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| CA3059449A1 (en) | 2017-04-24 | 2018-11-01 | Cocrystal Pharma, Inc. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
| TWI821343B (zh) | 2018-07-27 | 2023-11-11 | 美商共結晶製藥公司 | 流感病毒複製之抑制劑 |
| JP7472108B2 (ja) | 2018-09-10 | 2024-04-22 | コクリスタル ファーマ，インコーポレイテッド | ピリドピラジン系及びピリドトリアジン系インフルエンザウィルス複製阻害剤 |
| WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4644394A2 (en) | 2020-02-18 | 2025-11-05 | Gilead Sciences, Inc. | Antiviral compounds |
| CN115315252A (zh) * | 2020-03-22 | 2022-11-08 | 盈擘医药股份有限公司 | 用于预防或暴露后治疗感染或呼吸疾病的抗病毒组合物 |
| CN115884774A (zh) * | 2020-03-30 | 2023-03-31 | 富士胶片富山化学株式会社 | 冠状病毒感染症治疗剂 |
| CN111956630A (zh) * | 2020-08-20 | 2020-11-20 | 大连理工大学 | 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN118119624A (zh) * | 2021-08-20 | 2024-05-31 | 盐野义制药株式会社 | 具有病毒增殖抑制作用的核苷衍生物及其前药 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (cg-RX-API-DMAC7.html) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| US5388571A (en) * | 1987-07-17 | 1995-02-14 | Roberts; Josephine A. | Positive-pressure ventilator system with controlled access for nebulizer component servicing |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| KR100246082B1 (ko) | 1991-07-02 | 2000-04-01 | 인헤일, 인코오포레이티드 | 에어로졸화된약제를전달하는방법및장치 |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5622163A (en) * | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US6116234A (en) * | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| PT2251015E (pt) | 2000-10-18 | 2013-04-15 | Gilead Pharmasset Llc | Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal |
| BR0206614A (pt) * | 2001-01-22 | 2004-02-17 | Merck & Co Inc | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| WO2003062256A1 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| JP4398631B2 (ja) | 2002-07-12 | 2010-01-13 | 富山化学工業株式会社 | 新規なピラジン誘導体またはその塩並びにそれらを含有する抗ウイルス剤 |
| US20050196382A1 (en) | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
| CN101084232A (zh) * | 2004-10-19 | 2007-12-05 | 里普利科股份有限公司 | 抗病毒寡核苷酸 |
| SI2114980T1 (sl) | 2007-01-12 | 2012-11-30 | Biocryst Pharm Inc | Protivirusni nukleozidni analogi |
| JP2011513195A (ja) | 2007-05-10 | 2011-04-28 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | ウイルス感染およびがんの処置に使用するためのテトラヒドロフロ［３，４−ｄ］ジオキソラン化合物 |
| AP3076A (en) * | 2008-04-23 | 2014-12-31 | Gilead Sciences Inc | Carba-nucleoside analogs for antiviral treatment |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| US8455451B2 (en) * | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| EP2480559B1 (en) * | 2009-09-21 | 2013-07-03 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs |
| EA201200525A1 (ru) * | 2009-09-21 | 2012-09-28 | Гайлид Сайэнсиз, Инк. | 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения |
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| SI2834258T1 (sl) | 2012-03-13 | 2017-04-26 | Gilead Sciences, Inc. | 2'-substituirani karba-nukleozidni analogi za protivirusno zdravljenje |
-
2013
- 2013-03-11 SI SI201330567A patent/SI2834258T1/sl unknown
- 2013-03-11 EP EP18155061.7A patent/EP3351552B1/en active Active
- 2013-03-11 CN CN201380014318.9A patent/CN104185638A/zh active Pending
- 2013-03-11 ES ES16203290T patent/ES2709071T3/es active Active
- 2013-03-11 WO PCT/US2013/030196 patent/WO2013138236A1/en not_active Ceased
- 2013-03-11 KR KR1020147028523A patent/KR102068856B1/ko active Active
- 2013-03-11 EP EP21168626.6A patent/EP3932931B1/en active Active
- 2013-03-11 EP EP16203290.8A patent/EP3210993B1/en active Active
- 2013-03-11 CN CN201611121597.0A patent/CN106749272B/zh active Active
- 2013-03-11 JP JP2015500493A patent/JP6242378B2/ja active Active
- 2013-03-11 CA CA2866381A patent/CA2866381C/en active Active
- 2013-03-11 MX MX2014011009A patent/MX355267B/es active IP Right Grant
- 2013-03-11 EA EA201791916A patent/EA201791916A1/ru unknown
- 2013-03-11 PT PT137120432T patent/PT2834258T/pt unknown
- 2013-03-11 MD MDA20140112A patent/MD4496C1/ro active IP Right Grant
- 2013-03-11 EP EP13712043.2A patent/EP2834258B1/en active Active
- 2013-03-11 ES ES18155061T patent/ES2878087T3/es active Active
- 2013-03-11 US US13/793,557 patent/US9481704B2/en active Active
- 2013-03-11 EA EA201491548A patent/EA028928B9/ru unknown
- 2013-03-11 AU AU2013232378A patent/AU2013232378B2/en active Active
- 2013-03-11 ES ES13712043.2T patent/ES2621217T3/es active Active
- 2013-03-11 PL PL13712043T patent/PL2834258T3/pl unknown
- 2013-03-11 ES ES21168626T patent/ES3005115T3/es active Active
- 2013-03-11 NZ NZ629996A patent/NZ629996A/en unknown
-
2014
- 2014-09-11 IL IL234586A patent/IL234586A/en active IP Right Grant
- 2014-10-10 IN IN8505DEN2014 patent/IN2014DN08505A/en unknown
-
2016
- 2016-09-30 US US15/282,492 patent/US20170114086A1/en not_active Abandoned
-
2017
- 2017-06-21 JP JP2017121389A patent/JP6525441B2/ja active Active
- 2017-12-18 IL IL256397A patent/IL256397A/en unknown
- 2017-12-19 AU AU2017279590A patent/AU2017279590A1/en not_active Abandoned
-
2018
- 2018-06-22 US US16/016,369 patent/US10941177B2/en active Active
- 2018-12-26 JP JP2018242679A patent/JP2019069986A/ja not_active Withdrawn
-
2021
- 2021-01-28 US US17/161,065 patent/US11787832B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509983A5 (cg-RX-API-DMAC7.html) | ||
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2017523225A5 (cg-RX-API-DMAC7.html) | ||
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| JP2019500387A5 (cg-RX-API-DMAC7.html) | ||
| JP2015024998A5 (cg-RX-API-DMAC7.html) | ||
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| JP2017515901A5 (cg-RX-API-DMAC7.html) | ||
| MX2023014754A (es) | Métodos y composiciones dirigidos a pd-l1. | |
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| NZ739248A (en) | Inhibitors of hepatitis c virus | |
| EA202090514A1 (ru) | Противовирусное средство против гепатита в | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2017536395A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510038A5 (cg-RX-API-DMAC7.html) | ||
| CA2573346A1 (en) | Hepatitis c inhibitor peptide analogs | |
| AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2010501584A5 (cg-RX-API-DMAC7.html) | ||
| RU2010126056A (ru) | Органические соединения | |
| JP2020500866A5 (cg-RX-API-DMAC7.html) | ||
| JP2017522273A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518518A5 (cg-RX-API-DMAC7.html) | ||
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний |